Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
TNXP
TNXP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TNXP News
Tonix Pharmaceuticals Reports Positive Phase 3 Clinical Data for TONMYA
Jan 30 2026
NASDAQ.COM
TONMYA Shows Significant Pain Reduction in Fibromyalgia Treatment
Jan 30 2026
Newsfilter
Tonix Pharmaceuticals to Present at January 2026 Investor Conferences
Jan 06 2026
Globenewswire
Tonix Pharmaceuticals (TNXP) Enters $20M Securities Purchase Agreement with Point72
Dec 30 2025
Yahoo Finance
Tonix Pharmaceuticals Advances TNX-4800 for Lyme Disease with 2027 Testing Timeline
Dec 29 2025
Benzinga
Tonix Pharmaceuticals Enters $20M Stock Purchase Agreement with Point72 for 615,025 Shares
Dec 29 2025
Globenewswire
Tonix Pharmaceuticals Enters $20M Stock Purchase Agreement with Point72 for 615,025 Shares
Dec 29 2025
Newsfilter
Tonix Secures Exclusive Global Rights to TNX-4900, Advancing Non-Opioid Analgesic Development
Dec 16 2025
Globenewswire
Tonix Secures Exclusive Global Rights to TNX-4900, Advancing Non-Opioid Analgesic Development
Dec 16 2025
Newsfilter
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel to Enhance Product Commercialization
Dec 09 2025
Globenewswire
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel to Enhance Product Commercialization
Dec 09 2025
Newsfilter
Tonix Receives FDA Clearance for Phase 2 Study of TNX-102 SL in Major Depressive Disorder
Nov 24 2025
Newsfilter
Tonix Pharmaceuticals Receives FDA Approval to Advance TNX-102 for Depression Treatment
Nov 24 2025
SeekingAlpha
Reasons Behind the Surge in Tonix Pharmaceuticals (TNXP) Stock on Monday Morning
Nov 17 2025
Benzinga
Tonix Pharmaceuticals to Showcase Tonmya™ Poster at the 2025 ACR Convergence
Oct 21 2025
Newsfilter
Tonix to Progress Cyclobenzaprine to Phase 2 Trials for Depression
Oct 07 2025
SeekingAlpha
Show More News
